Literature DB >> 870519

Immunoreactive glucagon (IRG) responses to intravenous glucose in prediabetes and diabetes among Pima Indians and normal Caucasians.

S L Aronoff, P H Bennett, R H Unger.   

Abstract

Immunoreactive glucagon (IRG) response to a 3 min iv infusion of 25 g glucose was examined in 7 nondiabetic Caucasians, 8 nondiabetic, 8 prediabetic and 16 diabetic Pima Indians to define the normal IRG response and to determine if abnormalities of IRG suppression occur in diabetic and prediabetic Pima Indians. Fasting IRG levels were similar in the 3 nondiabetic groups. In response to the glucose infusion the maximum percentage fall in plasma IRG concentration was similar in the normal Caucasians (37+/-4%) and the normal (42+/-2%) and prediabetic Indians (43+/-3%). In the diabetic Indians the relative fall was less at all sampling times than among the prediabetic or normal Indians. No evidence of any differences in IRG suppression in prediabetic and normal Indians or normal Caucasians was found. Without detectable change in insulin levels during the first 10 min following the glucose infusion, IRG levels in the diabetics fell but to a lesser degree than that in the other groups.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 870519     DOI: 10.1210/jcem-44-5-968

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  12 in total

1.  Inappropriate suppression of glucagon during OGTT but not during isoglycaemic i.v. glucose infusion contributes to the reduced incretin effect in type 2 diabetes mellitus.

Authors:  F K Knop; T Vilsbøll; S Madsbad; J J Holst; T Krarup
Journal:  Diabetologia       Date:  2007-01-16       Impact factor: 10.122

2.  Roles of insulin resistance and beta-cell dysfunction in dexamethasone-induced diabetes.

Authors:  A Ogawa; J H Johnson; M Ohneda; C T McAllister; L Inman; T Alam; R H Unger
Journal:  J Clin Invest       Date:  1992-08       Impact factor: 14.808

Review 3.  Alpha cell function in health and disease: influence of glucagon-like peptide-1.

Authors:  B E Dunning; J E Foley; B Ahrén
Journal:  Diabetologia       Date:  2005-08-13       Impact factor: 10.122

4.  Dose-kinetics of pancreatic glucagon responses to arginine and glucose in subjects with normal and impaired pancreatic B cell function.

Authors:  R Assan; S Efendic; R Luft; E Cerasi
Journal:  Diabetologia       Date:  1981-11       Impact factor: 10.122

Review 5.  Insulin and glucagon signaling in the central nervous system.

Authors:  Beatrice M Filippi; Mona A Abraham; Jessica T Y Yue; Tony K T Lam
Journal:  Rev Endocr Metab Disord       Date:  2013-12       Impact factor: 6.514

6.  Chronic fractalkine administration improves glucose tolerance and pancreatic endocrine function.

Authors:  Matthew Riopel; Jong Bae Seo; Gautam K Bandyopadhyay; Pingping Li; Joshua Wollam; Heekyung Chung; Seung-Ryoung Jung; Anne Murphy; Maria Wilson; Ron de Jong; Sanjay Patel; Deepika Balakrishna; James Bilakovics; Andrea Fanjul; Artur Plonowski; Duk-Su Koh; Christopher J Larson; Jerrold M Olefsky; Yun Sok Lee
Journal:  J Clin Invest       Date:  2018-03-05       Impact factor: 14.808

7.  Glucagon receptor antagonism improves islet function in mice with insulin resistance induced by a high-fat diet.

Authors:  M Sörhede Winzell; C L Brand; N Wierup; U G Sidelmann; F Sundler; E Nishimura; B Ahrén
Journal:  Diabetologia       Date:  2007-05-04       Impact factor: 10.122

8.  GLUT-2 function in glucose-unresponsive beta cells of dexamethasone-induced diabetes in rats.

Authors:  M Ohneda; J H Johnson; L R Inman; R H Unger
Journal:  J Clin Invest       Date:  1993-10       Impact factor: 14.808

9.  Pharmacokinetics and pharmacodynamics of vildagliptin in patients with type 2 diabetes mellitus.

Authors:  Yan-Ling He; Denise Serra; Yibin Wang; Joelle Campestrini; Gilles-Jacques Riviere; Carolyn F Deacon; Jens J Holst; Sherwyn Schwartz; Jace C Nielsen; Monica Ligueros-Saylan
Journal:  Clin Pharmacokinet       Date:  2007       Impact factor: 6.447

10.  Plasma pancreatic glucagon response to blood glucose in experimental pancreatolithiasis in dogs.

Authors:  N Okumura; T Hayakawa; A Sakakibara; A Noda; T Kondo
Journal:  Diabetologia       Date:  1983-12       Impact factor: 10.122

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.